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BUILDING A METABOLIC BRIDGE BETWEEN GLYCOLYSIS AND SPHINGOLIPID 
BIOSYNTHESIS: IMPLICATIONS IN CANCER  
 





Cancer therapeutics has seen an emergence and re-emergence of two metabolic fields in 
recent years, namely bioactive sphingolipids and glycolytic metabolism. Anaerobic glycolysis 
and its role in cancer has been recognized in cancer biology over 90 years. In recent decades, the 
role of sphingolipids in cancer cell metabolism has gained recognition, notably ceramide’s 
essential role in programmed cell death and the role of the glucosylceramide synthase (GCS) in 
chemotherapeutic resistance. Despite this knowledge, a direct link between these two fields has 
yet to be concretely drawn. Herein, we show that in a model of highly glycolytic cells, generation 
of the glycosphingolipid (GSL) glucosylceramide (GlcCer) by GCS was elevated in response to 
increased glucose availability, while glucose deprivation diminished GSL levels. This effect was 
likely substrate dependent, independent of both GCS levels and activity. Conversely, leukemia 
cells with elevated GSLs showed a significant change in GCS activity, but no change in glucose 
uptake or GCS expression. In a leukemia cell line with elevated GlcCer, treatment with inhibitors 
of glycolysis or the pentose phosphate pathway significantly decreased GlcCer levels. When 
combined with pre-clinical inhibitor ABT-263, this effect was augmented and production of pro-
apoptotic sphingolipid ceramide increased. Taken together, we have shown that there exists a 
definitive link between glucose metabolism and GSL production, laying the groundwork for 
connecting two distinct yet essential metabolic fields in cancer research. Furthermore, we have 
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proposed a novel combination therapeutic option targeting two metabolic vulnerabilities for the 
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Sneaky, smart, conniving, stubborn. Evasive and yet ever-present. Our knowledge of “the 
emperor of all maladies” [1] has never run deeper, yet despite profound advances in its detection 
and treatment, most standard of care regiments are subject to grueling side effects at best, 
eventual resistance at worst. In its quest for novel treatment targets, cancer therapeutics has come 
full circle to revisit a metabolic hallmark of cancer cells first brought to light by Otto Warburg 
over 80 years ago, that of aerobic glycolysis. While revolutionary at the time, it is now 
recognized that this aberration is only a small piece of the puzzle of deregulated cancer cell 
metabolism. More recently, it has been shown that tumor cells present with altered sphingolipid 
profiles at baseline, in correlation with increasing aggressiveness and in response to 
chemotherapeutics. Despite these two seemingly unrelated facets of metabolism, it is understood 
that no metabolic alteration in cancer stands as an island unto itself, and we present data to show 
that the areas of glycolytic and sphingolipid metabolism are no exception to this rule.  
 
Alterations in Cellular and Systemic Glucose Metabolism in Cancer 
  
The role of aerobic glycolysis in cancer has been extensively reviewed by experts in the field 
of cancer metabolism [2-8]. To attempt to summarize this work would not give justice to the 
wealth of knowledge that exists, however a succinct overview of glycolytic metabolism in 
relation to the current topic will be presented here.  
In “normal” (differentiated, non-replicating) cells under normoxic conditions, the majority of 
the cell’s energy demands are generated through oxidative phosphorylation in the mitochondria, 
using reducing equivalents such as NADH and succinate generated through upstream catabolic 
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pathways such as glycolysis, beta oxidation and the tricarboxylic acid (TCA) cycle to form ATP. 
Only under conditions where oxygen is limiting do these cells revert to glycolytic metabolism for 
ATP production and subsequently produce excess amounts of lactate. On the other hand, 
transformed cells do not follow the same rules of metabolism. The Warburg Effect states that 
cancer cells take up increased amounts of glucose compared to their non-transformed 
counterparts and preferentially utilize glycolytic metabolism to produce ATP, even in the 
presence of oxygen, a phenomenon termed aerobic glycolysis [9-11]. Enigmatically, however, the 
alternative energetic pathway, oxidative phosphorylation, produces significantly more ATP than 
aerobic glycolysis per molecule of glucose. This begs the question: why do cancer cells 
preferentially utilize glycolysis, a “less efficient” pathway? Furthermore, contrary to what 
Warburg originally postulated, a great majority of cancer cells retain the ability utilize oxidative 
phosphorylation (OXPHOS) via functional, or mainly functional, mitochondria [12]. In contrast 
to initial beliefs, the purpose for shifting to aerobic glycolysis lies beyond fulfilling the energy 
requirements of rapidly proliferating cells; rather, increased glycolytic metabolism is utilized to 
provide the raw materials needed for rapid growth in the form of anaplerotic substrates. These 
substrates are produced through shuttling of glycolytic pathway intermediates into a variety of 
other metabolic pathways, such as the pentose phosphate pathway (PPP), the TCA cycle, 
nucleotide biosynthesis and glycogen synthesis [4, 5, 7, 8]. As will be discussed in further detail, 
one such pathway has remained largely unexplored, that of sphingolipid biosynthesis.  
In addition to the role of metabolic alterations at the cellular level in cancer cells, evidence 
has mounted at both the clinical and epidemiological level that systemic alterations in metabolism 
may also play a role in oncogenesis, progression and response to treatment. Obesity, 
hyperglycemia, hyperlipidemia and insulin resistance are correlated with increased risk of cancer 
development, more rapid disease progression and poorer response to treatment [13]. These 
disease states are associated with elevated circulating glucose and insulin levels. As such, one 
proposed mechanism for the increased incidence of cancer in these patients is activation of 
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mitogenic signaling pathways by glucose and insulin-like growth factors 1 (IGF1) through the 
IGF1 receptor (IGF1-R) [14], in addition to increased availability of glucose for uptake by cancer 
cells preferentially utilizing glucose metabolism. Retrospective studies have also shown that 
patients being treated with metformin and statins have a decreased incidence of cancer, although 
at least in some cancers this is believed to be independent of their effects on glucose and 
cholesterol metabolism, respectively [10, 11, 15-17]. Finally, both in vitro and in vivo studies 
have shown that both a ketogenic diet, which lowers circulating glucose levels [18], and caloric 
restriction [19] sensitize cancer cells to chemotherapeutics. Collectively, these studies indicate 
that alterations in metabolism at the systemic level, more specifically those which increases blood 
glucose levels, can promote oncogenesis and that metabolic therapeutics may serve to reverse this 
effect.  
 
Cancer Metabolism Extended: the P entose Phosphate Pathway and Glycogen Synthesis in 
Cancer 
  
While one of the most well-known metabolic hallmarks of transformed cells is increased 
utilization and reliance on glycolysis, the purpose of this aberration is merely as a conduit to 
further the overall goals of the cancer cell. In contrast to its role in “normal” cells, where it 
primarily serves to generate both ATP and reducing equivalents for OXPHOS, increased aerobic 
glycolysis in neoplastic cells functions to provide anaplerotic intermediates for shunting into 
various metabolic and anabolic pathways to support the requisite increase in biomass of the 
rapidly proliferating cell. The pentose phosphate pathway (PPP) is one of the key metabolic 
pathways [2, 8, 20]. Briefly, the PPP receives intermediates from glycolysis (primarily glucose-6-
phosphate (G6P), fructose-6-phosphate (F6P), and glyceraldehyde-3-phosphate (G3P)) for 
production of NADPH and ribose-5-phosphate (R5P). R5P is the precursor utilized in nucleotide 
biosynthesis to maintain rapid DNA synthesis in the highly proliferative phenotype. NADPH is 
an essential reducing agent in lipid and nucleotide biosynthesis, in addition to being a critical 
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cellular antioxidant. As testament to its key role in cancer cell metabolism, and glycolysis’ role as 
a supplier rather than an effector, it was shown that decreased PPP flux and concomitant 
increased glycolytic metabolism through increased pyruvate kinase M21 (PKM2) activity resulted 
in decreased tumor growth in a xenograft model [21]. Furthermore, increased activity glucose-6-
phosphate dehydrogenase (G6PD)2, either through overexpression or inhibition of negative 
feedback, was sufficient to transform murine NIH-3T3 fibroblasts and promote tumorogenesis in 
mice [22]. In relation to the current study, NADPH formation is essential for multiple aspects of 
sphingolipid metabolism: both in lipid biosynthesis, in forming the fatty acid chain to be added to 
sphingosine to form dihydroceramide, and in de novo ceramide synthesis itself (Fig. 1).  
While many other facets of oncogenic metabolism have been the topic of intense research, the 
role of glycogen synthesis in this phenotype remains comparatively less explored. As early as 
1925, it was shown that highly glycolytic tumor cells present with elevated glycogen levels [23], 
a phenotype now recognized as a hallmark of many clear cell carcinomas/sarcomas [24-28]. More 
recent studies have suggested that glycogen formation may function as a protective mechanism 
by serving as a store of glucose molecules to fuel anaerobic glycolysis during times of external 
stress [29]. In studies of tumor cell hypoxia, it has been shown that glycogen synthase is initially 
upregulated in response to oxygen deprivation, in [30-33], with a delayed increase in glycogen 
phosphorylase after prolonged hypoxia [34]. Furthermore, inhibition of glycogen phosphorylase 
in pancreatic tumor cells resulted in decreased glucose oxidation, and subsequent reduction in 
fatty acid and nucleotide biosynthesis [35]. This protective mechanism would arguably play a 
more important role in the pathogenesis of solid tumors, which are more susceptible to areas of 
oxygen deprivation; however, evidence does suggest that leukemic cells may be exposed to areas 
of hypoxia in the bone marrow microenvironment as well [36, 37]. Glycogen formation is 
                                                 
1 PKM2: pyruvate kinase isoform M2; catalyzes the rate-limiting, ATP-generating step of glycolysis in 
which phosphoenolpyruvate (PEP) is converted to pyruvate; the M2 form is found in self-renewing cells, 
and tumor cells 
2 G6PD: glucose-6-phosphate dehydrogenase: the rate-limiting enzyme for entry of G6P into the PPP (via 
conversion of G6P to 6-phosphogluconate) 
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catalyzed by glycogen synthase (GS), through addition of UDP-glucose to existing glycogen 
polymers. UDP-glucose formation depends on the formation of UTP, which relies on nucleotide 
biosynthesis for its formation, itself being fueled by production of intermediates from the PPP 
(see a simplified diagram below). Although to the best of our knowledge there are no studies that 
directly measure the level of UDP-glucose in neoplasms, studies in animal models of diabetes, 
which also take up elevated levels of glucose, present with elevated levels of UDP-glucose [38, 
39]. Lastly, the regulation of GS by glycogen synthase kinase (GSK) has recently become a topic 
of interest in cancer signaling, though its exact role in carcinogenesis is still largely unclear and 















Glycolytic Inhibitors / PPP Inhibitors in Cancer   
Given the significant role that aberrant metabolism plays in the neoplastic cell phenotype, 
development of therapies targeting the key control enzymes in the aforementioned pathways is 
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being actively pursued [2, 41-43]. Current agents are comprised of both pharmacological and 
RNAi mediated inhibition of nearly all facets of neoplastic metabolism, utilizing both established 
metabolic therapies and novel rational drug design [2]. 
Despite promising results at the pre-clinical and clinical level, targeting the deregulated 
bioenergetic and anabolic pathways in neoplastic cells is subject to the same critical pitfall as 
genotoxic therapies, which themselves target cells of the highly proliferative phenotype. 
“Normal” rapidly dividing cells, such as bone marrow-derived cells or gut epithelium, are subject 
to the non-discriminant effects of cytotoxic drugs, resulting in sometimes severe side effects 
associated with chemotherapy. Common short-term effects includenausea, emesis, fatigue, 
diarrhea, cachexia, peripheral neuropathy, myalgia, alopecia and myelosuppression; long-term 
side effects may include cardiotoxicity, ovarian failure in women, sterility in men, chemotherapy-
induced leukemia and cognitive dysfunction [44], notwithstanding drug-specific toxicities and 
side effects.  Furthermore, activation of T lymphocytes (i.e. rapid clonal expansion) relies on 
increased glucose uptake and reliance on aerobic glycolysis [45]. T lymphocytes play a key role 
in immune-derived targeting and eradication of cancer cells through recognition of tumor-
associated antigens [46]. Tumor cells have been shown to avoid detection from the immune 
system by inducing apoptosis of immune cells such as lymphocytes and antigen presenting cells, 
both in the surrounding microenvironment and systemically [47-50]. Further dampening of this 
immune response via inhibition of biometabolic pathways could be seen as adding insult to 
injury. However, it is proposed that there exists a therapeutic window in which treatments could 
target neoplastic/malignant cells, for example through isoform-selective therapies or careful drug 
titrations (reviewed in [51]). Another alternative involves the use of combinatory therapies, with 
one advantage being a lower effective dose of each individual drug, an approach which is 
commonplace in modern day chemotherapeutics [52]. A growing number of studies point to the 
therapeutic potential of combining metabolic inhibitors with targeted therapies [53, 54], such as 
the combination of hexokinase-II inhibitor 3-BrOP with mTOR inhibitor rapamycin [55]. In the 
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current study, we have provided support for this approach, in showing potent synergism exists 
between two metabolic inhibitors, 2-deoxyglucose3 (2-DG) and 6-aminonicotinamine4 (6-AN), 
and ABT-2635, a targeted inhibitor of the pro-apoptotic BCL2 family.  
 
Sphingolipids: Membranes and More 
Sphingolipids, originally sphingosin or “sphinx-like”, were named in respect of their 
enigmatic and complex nature by Johann Thudicum almost 150 years ago. Since that time, it has 
been established that hundreds of higher order sphingolipid species exist, thousands when taking 
into account varying chain lengths, a statistic daunting enough to scare off even the most 
dedicated of biologists. However, their role in cancer pathogenesis is undisputed, so though they 
may be the in-laws of the cancer biology family, they are here to stay and thus must be discussed. 
After a few glasses of wine, you may even grow to enjoy them. For the purpose of this 
discussion, a brief overview of sphingolipid metabolism will be presented as it relates to the 
current study. For a more thorough understanding of this topic, consult your nearest black hole 
(or the following review by Gault, Hannun and Obeid [56]). 
Sphingosine, an amino alcohol of 18 carbons formed from the condensation of palmitoyl 
CoA and serine, is the backbone of the entire sphingolipid family. Important players in this 
family are:  
i) ceramide, formed via N-acylation of a fatty acid chain (14-26 carbons) to the 
amide group of sphingosine by ceramide synthase (CerS); the central hub of 
all sphingolipid metabolism 
ii) sphingomyelin (SM), a key membrane phospholipid, formed via addition of 
phosphocholine (or less commonly phosphoethanolamine) to the C1 
hydroxyl of ceramide via sphingomyelin synthase (SMS) 
                                                 
3 2-deoxyglucose (2-DG): inhibitor of the rate-limiting enzyme of glycolysis, hexokinase (HK) through 
competitive inhibition with glucose 
4 6-aminonicotinamine (6-AN): inhibitor of 6-phosphogluconate dehydrogenase, an enzyme of the PPP 
which catalyzes the conversion of 6-phosphogluconate to ribulose-5 phosphate 
5 ABT-263 (navitoclax): structural analog of ABT-737; inhibitor of the BCL2 family anti-apoptotic 
proteins, namely Bcl-2, Bcl-w and Bcl-xL; induces apoptosis 
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iii) glucosylceramide (GlcCer), formed via addition of UDP-glucose to ceramide 
via glucosylceramide synthase (GCS); point of entry into the higher order 
glycosphingolipids 
iv) sphingosine-1-phosphate (S1P), formed via addition of a phosphate group to 




Under normal homeostatic conditions, ceramide can be generated via three pathways: 1) de novo 
synthesis 2) sphingomyelin hydrolysis 3) the salvage pathway (S1P breakdown). The de novo 
pathway relies on a critical enzyme, ceramide synthase (CerS), to catalyze the addition of a fatty 
acyl group to sphinganine to form (dihydro)ceramide (Fig. 1). As alluded to prior, part of the 
complex nature of sphingolipids is their ability to differ by fatty acid chain length. Six different 
isoforms of CerS exist and although some overlap exists, each isoform preferentially utilizes a 
specific fatty acyl chain length(s) [57]. For example, CerS5 preferentially uses long-chain fatty 
acids of 14 or 16 carbons to form either C14-Ceramide or C16-Ceramide. This has important 
implications for targeted therapies against sphingolipid enzymes, as it is postulated that 
ceramides (and derivatives such as glycosphingolipids) may play markedly different roles 
depending on the fatty acid chain length [58-60].  
Ceramides are synthesized de novo in the endoplasmic reticulum (ER), then transported to 
the Golgi. On the cytoplasmic face of the Golgi, GCS catalyzes the addition of UDP-glucose to 
form GlcCer. An important implication of this localization is that GCS has access to cytoplasmic 
contents and is not restricted to their transport across the Golgi membrane, a fact that will be of 
importance in discussion of its hypothesized role in cancer cell metabolism.  
Ceramide. Siskind et al. 2008  
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In addition to their role in regulation of membrane dynamics, sphingolipids are bioactive 
lipids involved in intracellular signaling, including roles in inflammation, cellular proliferation, 
oxidative stress and cell death. As defined by Hannun and Obeid, sphingolipids are regarded as 
bioactive due to the observation that “changes in (their) levels result in functional consequences” 
[61]. Among the many cellular functions in which sphingolipids play a role, one of the best 
characterized is their role in programmed cell death, or apoptosis [62]. Over 20 years have passed 
since the seminal work linking ceramide production to apoptosis was first published [63]. Since 
that time, there has been no shortage of studies linking cytokines, external stressors and apoptotic 
stimuli to production of ceramide and induction of apoptosis. Briefly, an external stimulus, such 
as TNF-α, leads to production of ceramide via activation of a metabolic enzyme, such as 
sphingomyelinase, which degrades SM to ceramide. Ceramide may then exert its proapoptotic 
effects through multiple mechanisms: 1) formation of ceramide-enriched domains and subsequent 
modulation of receptors or signaling molecules or 2) contributing to induction of mitochondrial 
outer membrane permeabilization (MOMP) through formation of ceramide channels in the 
mitochondrial outer membrane (MOM). (reviewed in [64]). The control of intracellular ceramide 
in response to cytotoxic agents is an important determinant in the outcome following a cytotoxic 
insult and thus has been implicated in a variety of disease states, cancer notwithstanding.  
 
Glycosphingolipids and Cell Signaling: Implications for Cancer 
 
In addition to their well-characterized role as structural components in the plasma membrane, 
certain species of GSLs have been widely implicated as pro-proliferative bioactive lipids in a 
variety of pathologies, including metabolic, kidney, and cardiovascular diseases, in addition to 
neoplasms [65-67]. Most evidence has pointed to the role of lactosylceramide and gangliosides as 
the major GSL players in this phenotype. GSLs have been shown to act as key players in various 
cellular signaling pathways, through formation of GSL micro- and macrodomains in the plasma 
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membrane, termed “glycosynaptic membranes” [68], in which they interact with transmembrane 
growth factor and cytokine receptors [69, 70], intracellular signal transducers [71], and cell 
adhesion proteins [72, 73].  
Of particular interest in recent decades is the role of GSLs in cancer. Clinical evidence shows 
that tumor cells have distinct glycosphingolipid profiles compared to non-transformed cells [50, 
74, 75], a phenotype associated with aberrant cell-cell adhesion and intracellular signaling, which 
play a significant role in tumor progression, metastasis, and response to treatment [76]. Much 
progress has been made in elucidating the mechanisms by which GSLs play a pathogenic role in 
solid tumors (for review, see ref [68, 77, 78]). In brief, such mechanisms include: i) association of 
GSLs with cell surface receptors and subsequent modulation of cellular signaling pathways, such 
as inhibition of tyrosine kinase activity of EGFR in breast cancer cells [74]; ii) modulation of 
integrin receptor function and subsequent control of invasion and motility, such as in bladder 
cancer [73]; iii) regulation of non-receptor intracellular signaling proteins, such as c-Src and Rho 
in melanoma [71]; and iv) “shedding” of GSLs into the extracellular tumor environment, 
inhibiting localized immune response and effectively paving the way for invasion and metastasis 
[47, 49]. Similarly, hematological malignancies have been found to have distinct GSL expression 
patterns in relation to disease subtype [79-84], although in contrast to solid tumors, less is known 
about their functional role in pathogenesis of blood cancers. As is recurrently the case in cancer 
biology, growing evidence suggests that the effect of GSL on cancer pathogenesis is both tumor- 
and GSL-species specific [85]. GSLs themselves are an extremely complex group of lipids 
composed of thousands of higher order species [86]. Despite this complexity, certain GSL sub-
species have garnered particular interest due to their variable expression in tumors, namely those 
of the ganglioside6 family. While overexpression of GSLs is associated with increased metastatic 
potential in some cancer types such as lymphoma and melanoma, it is inversely correlated with 
                                                 




invasion and metastatic potential in others, such as bladder and liver cancer (reviewed in [85]). 
Nevertheless, while aberrant GSL expression is increasingly considered a hallmark of cancers and 
may be useful as a biomarker in measuring disease progression, arguably one of those most 
extensively studied aspects of sphingolipid biology in cancer is its role in chemotherapy-induced 
apoptosis, or evasion thereof.  
In addition to their established role in proliferation, invasion and metastasis in tumors, GSLs 
have also been implicated in multidrug resistance (MDR). Treatment of cancer cells with 
chemotherapeutics elevates levels of the proapoptotic sphingolipid ceramide in a multitude of 
cancer cell lines during mitochondrial induced cell death [62, 64, 87, 88]. As a means of evading 
cell death, many drug-resistant cell lines reduce cellular ceramide levels via metabolism to other 
sphingolipid members, one such mechanism being conversion to GlcCer [65, 89]. 
Correspondingly, elevated levels of GCS and GlcCer are widely implicated in MDR in many 
cancers [90, 91]. The mechanism behind this observed phenomenon has been well characterized 
both at the in vitro and in vivo level. Briefly, a growing body of data suggests a strong 
relationship between GCS, MDR1, p-glycoprotein, drug efflux and resistance. P-gp is a 
membrane transport protein implicated in drug efflux-dependent and -independent resistance, 
encoded by the MDR1 gene. P-gp is also responsible for the transport of GlcCer from the 
cytosolic to luminal face of the golgi membrane [92], where it can be converted to more complex 
GSL species [93]. Studies have shown a direct correlation between increased drug resistance, 
GCS expression and p-gp message and protein levels [94]. It has also been shown that both 
GlcCer and GCS lead to increased MDR1 expression, through c-Src and beta-catenin signaling 
[91, 95]. This effect can be abated through pharmacological or genetic inhibition of GCS, which 
also resensitizes resistant cells to chemotherapeutics [96, 97]. Taken together, GCS plays a clear 
role in cancer pathogenesis and consequently has been an attractive target for the development of 
anti-neoplastic pharmaceuticals as both a primary treatment and a combinatorial treatment with 
cytotoxic therapies for the treatment of drug-resistant malignancies [98]. 
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As a final note, it is worth mentioning that the sphingolipids lactosylceramide and 
sphingosine-1-phosphate have been widely implicated in tumoro- and leukemogenesis, including 
roles in proliferation, metastasis and resistance, however are outside the scope of the current 
review. The reader may reference an in-depth review by Ogretman and Hannun for more 
information on this topic [99]. 
 
GCS Inhibitors in Cancer  
In keeping with the growing body of evidence implicating GSLs in cancer pathogenesis, 
significant investment has been made into the development of targeted GCS inhibitors. Despite 
resounding evidence that GCS acts as a potent sensitizing agent to cytotoxic and metabolic drugs, 
there persists conflicting views in the literature as to the exact mechanism by which GCS 
inhibitors exert their effects, and to what end sphingolipid metabolism plays a role. For this 
reason, a very brief overview of the evidence surrounding this topic will be presented, as the field 
will surely evolve in its understanding in the coming years.  
As previously discussed, there exists a positive correlation between p-gp and GCS levels in 
MDR. In targeting GCS as a means of reversing MDR, it has been shown in a wide range of 
cancer types that pharmacological and genetic inhibition of GCS synergizes with both standard of 
care chemotherapeutics [100-104] and with metabolic inhibitors such as resveratrol [105]. Given 
the relationship between GCS and p-gp in MDR, in addition to the fact that ceramide analog GCS 
inhibitors7 are also substrates of p-gp, the question was posed as to whether MDR reversal was 
truly a result of GCS, and not p-gp, inhibition. Evidence exists for both the former [106] and the 
latter [98, 107], indicating that indeed this topic must be explored in greater depth. 
What is almost undisputed in the literature, however, is that the sensitizing effect of GCS 
inhibition on cyototoxic therapies occurs almost exclusively in cells with established drug 
                                                 
7 Ceramide analog GCS inhibitors: as their name suggests, these inhibitors are ceramide analogs which 
compete for binding on GCS;  
 13 
 
resistance, as opposed to the parental, drug-sensitive cell line [98, 108]. In fact, one study has 
shown that treatment of non-resistant cells with PDMP and PPMP, ceramide analog inhibitors of 
GCS, results in resistance to the genotoxic drugs doxorubicin and cytarabine in a leukemia model 
[109], a phenomenon confirmed by data in the present study. 
While the mechanistic basis of sensitization by GCS inhibitors remains to be and must be 
elucidated, the fact remains that an overwhelming amount of evidence points to its efficacy. It is 
for this reason that its use in the clinic for the treatment of drug-resistant cancers has been 
advocated. The GCS inhibitor eliglustat tartrate (Genz-112638) is currently in phase III clinical 
trials for Gaucher’s Disease8 patients, and seems to be both effective and well tolerated. As such, 
this could be a promising option for the first human trials therapeutically targeting GCS, 
particularly in the context of drug resistant cancer. It should be noted, however, that because 
Genz-112638 [110] is a substrate of p-gp, it very poorly penetrates the blood brain barrier and 
thus would not be a viable option for the treatment of primary or metastatic brain tumors. 
However, design of a GCS inhibitor that would cross the BBB is currently an active area of 
research [111]. 
 
Cross-talk between Glycolysis and Sphingolipid Biosynthesis 
Given that GCS utilizes UDP-glucose to generate GlcCer, it would follow that increased 
glucose availability might elevate GSL levels. Despite this rather straightforward observation, a 
limited amount of data exists on the potential connection between these two entities, none of 
which has been evaluated in transformed cells. In vitro work has shown that renal epithelial cells 
cultured in high glucose have both elevated GlcCer and increased proliferation [38]. Work in rat 
models of type 1 diabetes mellitus (DM1) indicates a correlation between glucose uptake and 
GSL production. In these models, both UDP-glucose [112] and GSL levels [38, 39] are elevated 
                                                 
8 Gaucher’s Disease: an autosomal recessive lysosomal storage disorder due to a defiency of GBA, leading 
to accumulation of GlcCer in certain organs  
 14 
 
in the kidney in response to increased plasma concentrations of glucose. Conversely, inhibition of 
GSL production via targeting GCS improves glucose tolerance in animal models of DM1 [113]. 
Furthermore, reduction of GSL levels via inhibition of GCS increases both glucose uptake and 
glycolytic metabolism in leukemia cells [114], suggesting that a compensatory mechanism may 
exist by which the cell restores GSL levels through increased uptake and metabolism of the 
requisite substrates. Although these studies establish a connection between glucose availability, 
substrate production and GSL levels, they are inherently confounded by either: 1) the presence of 
disease states, for which the presence of external variables cannot be excluded or 2) the aberrant 
signaling pathways characteristic of transformed cells which undoubtedly influence glycolytic 




Despite the fact that increased glucose uptake and utilization is a hallmark of most cancers, 
and elevated glycosphingolipids are widely accepted as a prognostic marker of cancer progression 
and metastatic potential, an objective relationship between the two has yet to be drawn.  Herein 
we have established a link between the distinct, yet clearly interrelated metabolic fields of 
glycolytic and glycosphingolipid metabolism. We demonstrate that increasing glucose uptake and 
utilization in a non-transformed cell line, FL5.12, is sufficient to increase the levels of GSL, 
while withdrawing glucose from these same cells causes their dramatic depletion. Inhibition of 
glycolysis and the PPP is sufficient to deplete GSL levels in the same manner in both FL5.12 cell 
lines. Furthermore, we also present findings that this link persists in hematological malignancies 
and that manipulation of glycolytic and pentose phosphate pathway metabolism influences GSL 
levels in a leukemia cell line. Finally, we show that in a leukemia cell model, metabolic inhibitors 
2-DG and 6-AN synergize with pro-apoptotic BCL-2 inhibitor ABT-263 in inducing apoptosis. 
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Overall, these data demonstrate a clear link between glucose uptake and utilization and the 






Figure 1: An overview of sphingolipid metabolism.  
Formation of ceramide occurs through the de novo pathway (1), SM hydrolysis pathway (2), the 
salvage pathway (3), or β-Glucocerebrosidase (GBA) breakdown (4). The ratio of ceramide to 
glucosylceramide is an important factor in the survival of cells. Glucosylceramide is formed 
through addition of UDP-glucose to ceramide by glucosylceramide synthase (GCS) or the 




MATERIALS AND METHODS 
 
Cell Culture and Reagents   
FL5.12 WT and HG cells were kindly provided by Dr. Jeffrey Rathmell (Duke University 
Medical Center, Durham, NC) [115]. Human leukemia cells were purchased from ATCC. All 
cells were maintained in HyClone RPMI 1640 (Thermo Scientific #SH 30027) medium 
containing 10% FBS supplemented with 2 mM L-Glutamine, 10 mM HEPES (Gibco 15630-80) 
and 1X pen-strep (Gibco 15140-122); FL5.12 cells were additionally supplemented with 2 ng/ml 
recombinant mouse IL-3 and 1X β-mercaptoethanol. FL5.12 cells were maintained in the log 
growth phase between 5x105 and 2x106 c/ml. Leukemia cells were maintained in the log growth 
phase between 1x105 and 2x106 c/ml.  
 
Cell Viability Assay 
Cells growing in the log phase were seeded in 96- well dishes (2,500 FL5.12, U937, or 5,000 OCI 
AML 3 or 7,500 K562 cells per well) and immediately treated with the indicated drug 
concentrations in a total volume of 200 μl per well. All treatments were done in triplicate. 2-DG 
(#14325) and 6-AN (#10009315) were obtained from from Cayman and ABT-263 (cat#CT-
A263) from Chemietek (Indianapolis, IN, USA). Cells were treated for 48 hours, then incubated 
with 10% (20 μl) Alamar Blue reagent (cat#DAL1100) from Invitrogen (Grand Island, NY, 
USA). for 4 hours. Fluorescence of Alamar Blue reduction was determined on a BioTek HT 
Synergy plate reader (540 nm excitation, 594 nm emission). Wells containing only complete
 RPMI media and vehicle plus 20 μl of Alamar Blue were averaged and subtracted from all 
experimental readings. Drug treatment regimens were then normalized to either vehicle treated 
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cells or to wells containing only the IC30 of the indicated drug using a high-throughput method in 
excel (see below). Each graph shown is a representative experiment of at least three biological 
replicates unless otherwise indicated.  
 
Western Blot Analysis  
5x106 cells were harvested and lysed via sonication for 30s in 350 μl of RIPA lysis buffer (NEBL 
#9806S) with 100X protease and phosphate inhibitors. Protein concentrations were determined 
using BCA protein assay reagent from Pierce (#23223 and #23224). Cell homogenate was spun 
for 5 minutes at 500xg to pellet unlysed cellular debris. Supernatant was transferred to a new 
tube. Briefly, supernatant was diluted 1:10 and 25 μl of this dilution was added to 475 μl of BCA 
reagent. Pre-diluted BSA protein standards were utilized for preparation of a standard curve. 25 
μl of BSA standard and 25 μl of lysis buffer was added to 450 μl of BSA reagent. Standards and 
unknowns were then vortexed to mix and incubated in a 37° water bath for 30 minutes. 200 μl of 
standard and unknown were then plated in duplicate on a 96-well plate and measured on a 
spectrophotometer at 562 nm. Unknown values were extrapolated to the standard curve for 
quantification. Using these values, protein was diluted to 2 μg/ml. 40 μg (20 μl) of total protein 
was used for standard western blot procedure. Samples were boiled at 98° for 5 minutes before 
being run on SDS-PAGE gel (BioRad #345-0033) at 165V for approximately 30 minutes. The gel 
was then transferred using the iBlot Transfer System (Novex). Membranes were blocked in TBS-
T with 5% milk for 1 hour at room temperature. Primary antibody was added in the following 
dilutions: 1:1000 anti-GLUT1 (Santa Cruz #SC-7903), 1:2500 anti-HK1 (Cell Signaling #2024); 
1:10,000 anti-actin (Sigma #A5441), 1:10,000 anti-tubulin (Sigma #T5168). Anti-mouse and anti-
rabbit were added at a dilution of 1:10,000. Chemiluminescent detection was performed using 





In Situ Glucosylceramide Synthase Activity Assay 
5mg NBD-C6-Ceramide complexed with BSA (Life Technology #N22651) was dissolved in 150 
μl sterile dH2O (0.5mM NBD-C6-Ceramide and 0.5mM BSA) and stored at -20°C. 1x106 cells 
were plated in a 6-well plate in 2ml of complete RPMI 1640 media. 20 μM PDMP was added to 
the appropriate wells; remaining cells received DMSO as vehicle. Cells were incubated for 2 
hours at 37°C. All cells then received 2uM of NBD-C6-Ceramide and were incubated at 37°C for 
30 minutes. Cells were collected, spun at 1000xg for 5 min at 4°C, and supernatant was removed. 
Cells were washed 1X by adding ice-cold PBS (1000xg, 5 min, 4°C). Supernatant was removed. 
Lipids were extracted by Bligh and Dyer method [116]. Briefly, cells were resuspended with 260 
μl of ice-cold PBS and transferred to glass tubes. 666 μl of methanol was added to the cells and 
vortexed 2x30s. Cells were then kept on ice for 10 min. 333 μl of chloroform and 333 μl of water 
was added to tubes, which were vortexed two times for 30s then spun at 3000rpm for 5 min at 
room temperature. The lower phase (containing the lipids) was transferred to a new set of glass 
tubes and lipids were dried down by nitrogen gas. Lipids were then resuspended in 30 μl of 
chloroform/methanol (2:1, v/v) and loaded onto TLC plates (Millipore #1.05644.0001) for 
separation.  NBD-Glycosphingolipids were used as standards. The chromatogram was developed 
in a solvent system consisting of chloroform/methanol/30%ammonium hydroxide/water 
(350:150:18:7: vol/vol). TLC plates were scanned on a BioRad phosphorimager. Band density 
was quantified by Quantity One software (count/mm2). NBD-GlcCer were normalized to total 
(NBD-Ceramide + NBD-GlcCer), and the normalized to total cell number and time.  
 
Quantitative Real-Time Reverse Transcription PCR 
  
Total RNA was extracted using EZNA Total RNA Kit I (OMEGA bio-tek #R6834) according to 
the manufacturer’s protocol. The concentration and quality of total RNA preparations were 
evaluated by NanoDrop. cDNA was synthesized from 1 ug of total RNA using the iScript cDNA 
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Synthesis Kit for first-strand synthesis (BioRad # 170-8890). Quantitative real-time PCR (qPCR) 
was performed on a Bio-Rad CFX96 Real-Time detection system using SsoFast EvaGreen 
Supermix (BioRad # 172-5202). Standard reaction volume was 25 μl containing 12.5 μl 
Supermix, 9.5 μl dH2O (Sigma), 400 nM specific oligonucleotide primers, and 25 ng of cDNA 
template. β-Actin was used as reference gene. The PCR reaction was carried out as follows for 
UGCG, GBA and β-actin: enzyme activation 95°C, 30s; denaturation 95°C, 5s; annealing 60°C 
5s; 40 cycles total.  For FL5.12 cells, the ΔΔCT method was used, and HG was normalized to 
WT. For leukemia cells, absolute quantification of expression was calculated via normalization to 
a previously validated standard curve for β-actin. Primers were validated for temperature and 
efficiency prior to use in qPCR. Primer sequences are as follows:   
 
Glucose Uptake  
1x106 cells were plated in glucose-free RPMI 1640 media supplemented with 10% dialyzed FBS. 
Cells were incubated at 37°C for 30 minutes following plating to allow equilibration with media. 
Following incubation, cells were given 25μl of 14C deoxy-glucose (0.1μCi/μl) for one hour, then 
washed three times with ice cold PBS. Cells were lysed in 500 μl 0.1% SDS. 400μl of lysate was 
added to 5ml Microscint 40 scintillation fluid (Perkin Elmer) and mixed well by shaking. Counts 
were measured on a Tri-Carb 2910 liquid scintillation analyzer (Perkin Elmer). Remaining lysate 
Gene Sense Anti-Sense 
hACTB ATTGGCAATGAGCGGTTCC GGTAGTTTCGTGGATGCCACA 
hUGCG GAATGGCCGTCTTCGGGTT AGGTGTAATCGGGTGTAGATGAT 
hGBA CCGATGGCTCTGCTGTTGTG CAGGTAGGTGTGAATGGAGTAGC 
mUGCG CCTTGTTCGGCTTCGTGCTCTTC TGCTATACGGCTGTTTGTCTGTTGC 
mGBA TGGATGCTTATGCTAAGTATGG CACGGGAAATGAAGTCTCTCTG 
mACTB AGATTACTGCTCTGGCTCCTAG CCTGCTTGCTGATCCACATC 
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was quantitated with the BCA Assay as described above.  Counts were normalized to μg protein 
concentration. 
 
Intracellular Lipid Measurement 
5x106 cells were seeded in 10 cm dishes containing complete RPMI without antibiotics and 
treated with the indicated drug(s) or appropriate vehicle in biological triplicates. At the indicated 
times, cells were harvested, washed two times in 5 mL of ice cold  PBS, then cell pellets were 
snap frozen in liquid nitrogen. Quantification of sphingolipid species was performed by the 
Lipidomics Core Facility at the Medical University of South Carolina (MUSC) on a Thermo 
Finnigan TSQ 7000, triple-stage quadrupole mass spectrometer operating in a Multiple Reaction 
Monitoring (MRM) positive ionization mode as described [117]. Excess lipids were obtained and 
extracted using the Bligh and Dyer method. Data were normalized to total lipid phosphate.  
 
Statistical Analysis 
A one-way ANOVA with Halm-Sidak post-test was used for samples n>2. A two-tailed t-test was 
used for samples where n=2. Unless otherwise indicated: all data points represent the compilation 
of at least three biological triplicates; data are represented as average +/- SD; dose-response 
graphs are a representative graph of an experiment conducted in triplicate; significance was 





Glucose Availability Dictates Glycosphingolipid Levels in Highly Glycolytic Cells 
  In order to determine whether glucose availability in and of itself is sufficient to drive GSL 
production we utilized the murine IL-3 dependent FL5.12 hematopoietic progenitor cell line over-
expressing the glucose transporter Glut-1 and the rate-limiting glycolytic enzyme HK-1 (herein 
FL5.12 HG) [115]  (Fig. 2A). This cell line represents a model of highly glycolytic cells 
independent of intracellular or extracellular alterations seen in disease states. As expected, 
FL5.12 HG cells took up 83-fold more glucose as compared to their wild-type counterparts (Fig. 
2B). Furthermore, over-expression of HK1 in HG cells leads to a significant decrease in their 
sensitivity to treatment with the HK-1 competitive inhibitor 2-DG (IC50=0.33 mM vs 1.7 mM for 
wild-type and HG, respectively) (Fig. 4A). This was further confirmed by treatment of both cell 
lines with a single dose 2-DG and determining the relative cell viability.  At 1 mM of 2-DG the 
cell growth of wild-type cells was inhibited by 65%, whereas HG cells were only inhibited by 
27% (Fig. 2C).  
Previous studies indicated that increased glucose availability resulted in increased GSL levels 
in DM1 mice [39], therefore we assessed if the same phenomenon would occur in our model of 
highly glycolytic cells. Indeed, increased glucose availability resulted in elevated GSL levels in 
FL5.12 HG cells compared to wild-type cells (Fig. 3A). This led us to question whether glucose 
withdrawal would correspondingly result in decreased GlcCer levels. Indeed, wild-type cells 
withdrawn from glucose for 18 hours showed a marked decrease in GlcCer levels compared to
cells continuously cultured in glucose (Fig.3B).  
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To investigate the extent to which glucose availability impacts enzymatic control of GlcCer 
formation, we measured the expression and activity of GCS and β-Glucocerebrosidase (GBA), 
the enzymes responsible for the anabolic and catabolic formation of GlcCer, respectively (Fig. 
3C). Although GlcCer levels were dramatically elevated in HG cells over wild-type, increased 
glucose availability did not significantly alter the expression of GCS or GBA (Fig. 3C).  
Moreover, GCS activity was also not increased in FL5.12 HG cells compared to wild-type (Fig. 
3D).  
Collectively, these data indicate that glucose availability impacts GSL levels, and that in non-
transformed cell lines increased GSL production appears to be a substrate driven process 
relatively independent of GCS expression or activity. 
 
Inhibitors of Glycolytic Metabolism and the Pentose Phosphate Pathway Decrease 
Glycosphingolipid Levels 
  
Given that glucose availability plays a clear role in GSL formation (Fig.2B and 3A), we 
determined whether selective inhibition of bioenergetic pathways downstream of glucose uptake 
would decrease GSL levels. FL5.12 cells were treated in a dose response manner with 2-DG or 6-
AN to establish the respective IC50 of each cell line for these inhibitors (Fig. 4A-B). WT and HG 
cells were then treated for 8 hours with 2-DG or 6-AN IC50 and total hexosylceramide (glucosyl- 
and galactosylceramide) levels were measured via HPLC-MS/MS. As shown in Fig. 4C, 
hexosylceramide levels decreased following treatment with 2-DG in both WT and HG cells. 
Treatment with 6-AN also decreased hexosylceramide levels in both cell lines, however this 
effect was blunted in HG cells, an interesting result given that HG cells were found to be slightly 
more sensitive to 6-AN. 
Overall, these data support the hypothesis that GSL levels are at least in part influenced by 




Glycosphingolipid Levels in Leukemia Cells are Primarily Dictated by GCS Activity 
FL5.12 HG cells provided an excellent, syngeneic in vitro model for establishing a 
relationship between increased glucose availability and GSL production, however they inherently 
lack the aberrations in intracellular signaling present in cancer cells. In order to examine if this 
relationship persists in transformed cells, we utilized four leukemia and lymphoma cell lines 
(collectively “leukemia” cell lines for simplicity), U937, OCI AML3, RAJI and HEL (Fig. 5A).  
Baseline GlcCer levels were measured via HPLC-MS/MS. GlcCer levels were elevated in U937 
and OCI AML3 cell lines, while decreased in RAJI and HEL when compared to cultured human 
cord blood CD34+ cells (CB12011A) (Fig. 5B). Given that increased glucose availability 
elevated GlcCer levels in our model of highly glycolytic FL5.12 cells, we examined whether 
leukemia cells with elevated GlcCer also took up more glucose.. U937 and OCI AML3 cells took 
up elevated, albeit non-significant glucose compared to RAJI and HEL cells (Fig. 5C).  
To elucidate the extent to which glucose availability correlates with enzymatic GlcCer 
production in these cell lines, we again measured GCS expression and activity.  Similar to FL5.12 
cells, there was no significant change in the mRNA expression of either GCS or GBA across the 
leukemia cell lines (Fig. 6A and 6B). In contrast to FL5.12 cells, however, GCS activity 
positively correlated with GlcCer levels in our panel of leukemia cells (Fig. 6C). Collectively, 
these results suggest that increased GlcCer levels in leukemia cell lines may be primarily 
influenced by increased GCS activity. Glucose availability may influence baseline GlcCer levels 
in some leukemia cells, perhaps through the production of substrates formed during and 
downstream of glucose metabolism.  
 
Treatment of Drug Sensitive Leuk emia Cells with Sublethal Doses of GCS Inhi bitors 
Confers Resistance to Doxorubicin 
 A growing body of data indicates that GCS inhibition sensitizes to antineoplastic agents in 
the context of MDR [89-93], while a recent study showed that in that context of drug-sensitive 
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cells, it inhibition of GCS may play a cytoprotective role upon combination with genotoxic drugs, 
such as daunorubicin [109]. Preliminary data from our lab provide circumstantial confirmation of 
this result. To establish sensitivity to doxorubicin9, U937 and 5 other leukemia cell lines were 
treated with increasing doses of doxorubicin and assayed for cell viability (data not shown). 
While all cell lines tested were sensitive to doxorubicin treatment, U937 was among the most 
sensitive, evidenced by 100% decrease in cell viability at 1 μM.  In order to determine the effect 
of GCS inhibition on sensitivity to doxorubicin, dose response assays in U937 cells were first 
performed to establish the IC50 of doxorubicin (55 nM), PDMP10 (72 μM) and PPMP (11 μM) 
(data not shown). U937 cells were treated with doxorubicin in a dose-response manner alone or in 
combination with the IC30 of PDMP or PPMP. Cells were also treated with increasing doses of 
PDMP or PPMP with addition of doxorubicin IC30.  PDMP in combination with doxorubicin 
resulted in marked resistance to the drug, and vice versa (Fig. 7A-B). The same result was seen 
upon dose response treatment with PPMP, although in this case resistance was even more striking 
(Fig 7C-D).  
 As a note with respect to these results, it should be acknowledged that while the calculated 
IC30 of both PDMP and PPMP were used, in actuality the calculated inhibition was 5% and 50%, 
respectively. These data are preliminary results, and will require optimization and duplication in 
order to confirm. 
 
Inhibitors Of Glycolysis and PPP Synergiz e with ABT-263 to Inc rease 
Ceramide:Glycosphingolipid Ratios  
 
Anti-apoptotic BCL-2 family proteins are up-regulated in many cancers, especially leukemias 
[118]. We have shown previously that that PDMP, an inhibitor of GCS activity, sensitizes U937 
                                                 
9 Doxorubicin is a derivative of daunorubicin, both being anthracyclines with anti-tumor properties. 
Doxorubicin has a higher therapeutic index.   
 
10 PDMP: a well-established ceramide analog inhibitor of GCS; PPMP is a derivative of PDMP with a 
markedly higher potency 
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cells to treatment with ABT-263, a small molecule inhibitor of anti-apoptotic BCL-2 family 
proteins Bcl-2, BCL-xL and Bcl-w [103]. To evaluate whether inhibition of the proposed 
metabolic pathways upstream of glycosphingolipid formation also synergize with ABT-263 in 
killing leukemia cells, we tested the combination of 2-DG or 6-AN with ABT-263 in U937 cells. 
Cells were treated in a dose-response manner for 48h, either with increasing doses of 2-DG and 
the IC30 of ABT-263 or vice versa (Fig. 8A). The same treatment pattern was followed using 6-
AN and ABT-263 (Fig. 8B). The presence of 2-DG or 6-AN dramatically decreased the dose of 
ABT-263 required to induce cell death. The IC50 for ABT-263 alone was 5 μM, however upon 
addition of 2-DG decreased by 12.5-fold to 0.4 μM. Similarly, the IC50 of ABT-263 decreased 
even more dramatically in combination with 6-AN, from 5μM to 0.15 μM, a 37-fold reduction. 
The same phenomenon was observed when ABT-263 was added at a constant dose to increasing 
doses of 2-DG or 6-AN, reducing the IC50 by 14-fold and 18-fold, respectively.  
If 2-DG and 6-AN blocked the pathways which provide the requisite substrates for GlcCer 
production, then treatment of cells with these inhibitors should cause a significant decrease in the 
total GlcCer levels. Ceramide, GlcCer and lactosylceramide levels were measured via HPLC-
MS/MS following 8-hour treatment with 2-DG, 6-AN and ABT-263 alone or in combination. 
Increases in intracellular ceramide are a hallmark of apoptotic cell induction [62, 64]. Indeed, 
following treatment with ABT-263, which induces cell death through induction of mitochondrial-
induced apoptosis, ceramide levels significantly increased. Furthermore, upon addition of 2-DG 
or 6-AN, ceramide levels synergistically increased compared to ABT-263 alone. As expected, 2-
DG or 6-AN alone did not significantly increase ceramide levels, given that at low concentrations 
they inhibit cell growth rather than induce apoptosis [119]. Notably, however, 2-DG and 6-AN 
caused a dramatic drop in GlcCer levels by 45% and 23%, respectively, a decrease further 
augmented by addition of ABT-263 (an additional 20% and 40%, respectively) (Fig. 9). The role 
of lactosylceramide in cell death is not as clear, however it is worth noting that treatment with 6-
AN, not 2-DG, decreased lactosylceramide levels, as well (Fig. 9).   
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These data further support the hypothesis that both glycolysis and the PPP are instrumental in 
providing substrates for GlcCer formation. Furthermore, nutrient deprivation via metabolic 
inhibition synergizes with ABT-263 in inducing cell death via ceramide accumulation within the 
cell, data which is consistent with many other studies showing that metabolic inhibition of cancer 

















































Figure 2: FL5.12 cells overexpressing GLUT1 and HK1 are highly glycolytic.  
a) FL5.12 HG cells stably overexpress glycolytic enzymes GLUT1 and HK1. Overexpression of integral 
membrane protein GLUT1 and HK1 was confirmed by western blot. HK1 is not endogenously expressed in 
wild-type FL5.12 cells. b) FL5.12 WT and HG cells were grown in glucose-free media for one hour, 
incubated with 14C 2-Ddeoxy-glucose for one hour, then collected and counted by scintillation. FL5.12 HG 
cells took up significantly more glucose than their WT counterparts. d) FL5.12 cells were treated for 48 
hours with 1 mM 2-DG and cell viability was measured using Alamar Blue reduction. Graph B represents 






























































































































































Figure 3: Glucosylceramide levels are elevated in a model of highly glycolytic cells.  
a) Cellular lipids were harvested from FL5.12 cells growing in log phase. Glucosylceramide levels were 
determined by HPLC-MS/MS. HG levels were normalized to WT. b) FL5.12 wild-type cells were glucose-
deprived for 18 hours and the total amount of cellular glucosylceramides was determined by HPLC-
MS/MS. c) FL5.12 cells were grown for 24 hours in log phase with complete media then analyzed for 
expression of GCS and GBA via qPCR. WT expression was set to 1.0 and HG expression was normalized 
to wild-type. GCS and GBA expression decreased compared to wilt-type cells. d) GCS activity was 
measured in FL5.12 wild-type and HG cells. Cells were grown in complete media for 2 hours and then 
analyzed for GCS activity via addition of NBD-ceramide and separation on TLC. Graphs B and D represent 















































Cells were treated for 48 hours with a) 2-DG (0.06-150 mM) or b) 6-AN (0.06-135 μM) then measured for 
cell viability via AlamarBlue reduction. HG cells are more resistant to treatment with HK-1 competitive 
inhibitor 2-DG vs wild-type cells (IC50=0.33 mM vs 1.7 mM for wild-type and HG, respectively, at 48 
hours).  No significant different was seen in response to 6-AN treatment (IC50=2.9 μM vs 2.6 μM  for WT 
and HG, respectively). c) FL5.12 cells were treated with 2-DG or 6-AN at their respective IC50 for 8 hours. 
Total hexosylceramide levels were determined via HPLC-MS/MS. Long-chain ceramides (C16-20) and 
very long chain ceramides (C22+) are shown. Lipids levels were normalized to viable cell number. 
 































































































































 Figure 5: GlcCer levels differ among a panel of leukemia cell 
lines. 
a) Leukemia cell lines used in the present study.  b) Cellular lipids 
were harvested from leukemia cells in log phase growth. Total 
cellular GlcCer levels were measured by HPLC-MS/MS and 
normalized to cord blood cell line CB12011A. c) Glucose uptake 
was measured in four leukemia cell lines. Cells were grown in 
serum-free glucose-free media 30 minutes, incubated with 14C 2-D-
deoxy-glucose for one hour, then collected and counted by 































































































































Figure 6: GCS activity is increased in 
leukemia cell lines with elevated GSLs. 
  
 a, b) Leukemia cells were cultured in log phase 
growth with complete media for 24 hours and 
then analyzed for expression of GCS and GBA by 
qPCR. c) GCS activity was measured in leukemia 
cells. Cells were grown in complete media for 2 
hours, then analyzed for GCS activity via addition 






























































































































Figure 7: Preincubation with GCS Inhibitors confers resistance to doxorubicin in leukemia cells.  
U937 cells were treated with a) increasing doses of doxorubicin (0.3-670 nM) alone or in combination with 
PPMP IC30 (11 μM); b) increasing doses of PPMP (4.1-30 μM) in combination doxorubicin IC30 (21 nM); 
c) increasing doses of doxorubicin (0.3-670 nM) alone or in combination with PDMP IC30 (72 μM); d) 
increasing doses of PDMP (18.3-135 μM) alone or in combination with doxorubicin IC30 (21 nM). Cell 
























































































































Figure 8: Inhibitors of glycolytic metabolism and the pentose phosphate pathway synergize with an 
inhibitor of anti-apoptotic BCL2 proteins. 
 a,b) U937 cells were incubated for 48 hours with a) increasing doses of 2-DG plus either vehicle or ABT-
263 IC30 (5 μM) or b) increasing doses of ABT-263 plus vehicle or the IC30 of 2-DG (1.7 mM) for 48 
hours. The relative number of viable cells was determined using reduction of AlamarBlue reagent. c,d) 
U937 cells were incubated for 48 hours with c) increasing doses of 6-AN plus vehicle or IC30 (5 μM) of 
ABT-263 or d) increasing doses of ABT-263 plus vehicle or the IC30 of 6-AN for 48 hours. Cell viability 
was determined using reduction of AlamarBlue reagent. Doses: 2-DG: 33 μM to 170 mM; 6-AN: 13.3 nM 













Figure 9:  Inhibitors of glycolytic metabolism and the pentose phosphate pathway synergize with an 
inhibitor of anti-apoptotic BCL2 proteins to increase ceramide:glycosphingolipid ratios.  
a) U937 cells were treated with vehicle (DMSO), ABT-263 IC30 (5 μM), 6-AN IC30 (1.7 μM), or the 
combination of 6-AN and ABT-263 at their respective IC30 8 hours. Cells were harvested and lipids were 
analyzed via HPLC/MS-MS. b) U937 cells were treated vehicle (DMSO), ABT-263 IC30 (5 μM), 2-DG 
IC30 (5 mM), or the combination of 2-DG and ABT-263 at their respective IC30. Cells were harvested and 
lipids were analyzed via HPLC/MS-MS. 
 





























































There exists a limited amount of data linking glucose availability in cells to production of 
glycosphingolipids (GSLs), the seminal work being performed by the Shayman Group [38, 39] in 
rat models of DM1. Furthermore, this phenomenon has never been shown outside of a metabolic 
disease state. In the present study we have shown that there exists a definitive link between 
glucose availability and GSL formation, independent of aberrant intracellular signaling pathways 
of cancer cells or the influence of the extracellular environment present in disease states. Glucose 
transporter 1 (GLUT1) and Hexokinase II (HK2) are often overexpressed in response to 
oncogenic signaling pathways to support the highly glycolytic nature of the cancer cell [121, 
122]. Our model of highly glycolytic cells, FL5.12 HG, overexpressed the same enzymes in a 
non-transformed hematopoietic cell line (Fig. 2A), which increased glucose availability (Fig. 2B) 
and significantly elevated GlcCer levels (Fig. 3A). On the other hand, glucose withdrawal in 
wild-type FL5.12 cells correspondingly decreased GlcCer below baseline levels (Fig. 3B), thus 
supporting our hypothesis that glucose availability in and of itself can directly influence 
glycosphingolipid levels. We found that this is primarily a substrate-driven process, given that 
neither expression nor activity of GCS, the enzyme responsible for GlcCer formation, was 
significantly altered between the two cell lines.  
It is taken as canon in cancer biology that a hallmark of neoplastic cells is reliance on aerobic 
glycolysis over oxidative phosphorylation. In order to support the increased utilization of aerobic 
glycolysis for production of ATP, many cancers, solid tumors and blood cancers inclusive, also 
take up elevated amounts of glucose [3, 6, 9].  A growing body of evidence that suggests one of 
the main advantages of and reliance on aerobic glycolysis is the production of intermediates for 
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shunting into bioenergetic and anaplerotic pathways. Production of such substrates serves to 
support the requisite increase in biomass of the rapidly dividing cell. For example, increased flux 
into the PPP results in increased nucleotide formation via production of ribose-5-phosphate. In 
keeping the “biomass hypothesis”, we tested whether inhibition of two bioenergetic pathways, 
glycolysis and the PPP, would result in decreased GSL levels. Indeed, treatment with 2-DG and 
6-AN decreased hexosylceramide levels in both cell lines (Fig. 4C). These results suggested that 
pathways downstream of glucose uptake may provide the requisite substrates for production of 
hexosylceramides, namely GlcCer. Therefore, increased glucose uptake elevates flux into these 
pathways and subsequently levels of these intermediates, thereby increasing GSL levels. 
Leukemia and lymphoma are umbrella classifications for complex and heterogeneous groups 
of bone marrow- and lymphatic-derived malignancies, respectively, each with its own unique 
aberrations in cellular signaling and metabolic profiles. As such, we chose to study the 
relationship between glucose metabolism and GSL levels irrespective of genetic background in a 
panel of leukemia and lymphoma cell lines (U937, OCI AML3, RAJI, HEL) (Fig. 5A). Given that 
cancer cells are already highly glycolytic in nature, it is not surprising that a significant difference 
in glucose uptake was not observed between the leukemia cell lines (Fig. 5C), or that GlcCer 
levels are not entirely dependent on its uptake, although from the data it could be inferred that 
differential uptake may play a role. On the other hand, we found that GCS activity is significantly 
increased in cell lines with elevated GlcCer levels. This is in contrast to FL5.12 HG cells, where 
GlcCer levels directly correlated to glucose uptake, without significantly altering GCS expression 
or activity. Overall, these data indicate that other mechanisms may be at play in transformed cells 
in addition to regulation of substrate uptake and GCS enzyme expression, which may include 
regulation of substrate activity. As the following data would indicate, this may be related to 
preferential shunting of glucose into pathways essential for GlcCer and GSL production in cell 
lines with elevated GSL levels. 
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Prior data in our lab showed that PDMP, a ceramide analogue inhibitor of GCS, synergizes 
with ABT-263, an inhibitor of pro-apoptotic BCL-2 like proteins, in inducing apoptosis in 
leukemia cells [103]. In the present study we showed that both 2-DG and 6-AN, inhibitors of 
glycolysis and the PPP, respectively, also synergized with ABT-263 in U937 cells. Furthermore, 
treatment with 2-DG and 6-AN led to a significant reduction in GlcCer levels, which were further 
decreased upon co-treatment with ABT-263. ABT-263 alone increased the pro-apoptotic lipid 
ceramide, an effect which was significantly augmented upon addition of 2-DG or 6-AN. Notably, 
neither 2-DG nor 6-AN increased ceramide levels significantly on their own, indicating that these 
two metabolic inhibitors act synergistically to augment the effect of ABT-263.  
On the basis of the observations that 1) increased glucose uptake leads to increased GSL 
levels and 2) inhibition of metabolic pathways such as glycolysis and the pentose phosphate 
pathway reduce GSL levels, we hypothesize that in addition to producing intermediates for 
biosynthetic reactions which fuel the highly proliferative state of cancer cells, formation of these 
substrates also serves to increase the production of glycosphingolipids via GCS. An overview of 
the proposed mechanism is provided in Fig. 11. Briefly, through shunting into the PPP, glucose 
provides intermediates such as ribose-5-phosphate for synthesis of nucleotides such as UTP. 
Increased glucose uptake also leads to increased flux into glycogen synthesis [123], which forms 
UDP-glucose from UTP and glucose. Increase in glucose availability has been previously shown 
to increase intracellular UDP-glucose levels in the kidney in rat models of DM1 [112, 124], an 
increase which was later shown to elevate GSL levels [38, 39]. In this work, it was hypothesized 
that UDP-glucose is utilized by GCS to form GlcCer through its addition to ceramide in diabetic 
conditions within the kidney (Fig. 10). Accordingly, we hypothesize that in highly glycolytic 
cells, such as cancers, one role of increased glucose uptake is to form UDP-glucose for use by 
GCS to form GlcCer, in an attempt to deplete ceramide levels and evade apoptosis.  It is also 
plausible that other pathways could play a role in GlcCer formation, such as generation of 
NADPH for use as a cofactor in de novo ceramide synthesis. The PPP has also been implicated 
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recently in the transformed phenotype of cancer cells [20]. Furthermore, glucose-derived 
pyruvate is utilized by the TCA cycle in transformed cells for production of anaplerotic 
intermediates such as citrate for fatty acid synthesis [4], a mechanism which would support an 
increase in overall production sphingolipids, including GlcCer. Future work in this area will focus 
on the exact substrates elevated in cancer cells in response to increased glucose availability for 
GlcCer formation, although we speculate that these will include: UDP-glucose, palmitoyl-COA, 
fatty acids, and NADPH.  
Taken together, down what therapeutic road do the present results lead us? Current standard 
of care in many cancers focuses on targeting the highly proliferative phenotype of cancer cells 
with genotoxic drugs such as platinums, anthracyclines, and pyrimidine analogs, among others. 
However, these therapies are limited by the near inevitability of acquired resistance and 
metastatic relapse [125], often of a more aggressive phenotype and association with poor patient 
outcome [126-129]. By utilizing therapeutics which do not rely on targeting rapidly dividing 
cells, but instead which target other intrinsic properties of malignant cells, it may be possible to 
avoid development of resistance or disease relapse. Such is the theory behind the combination of 
2-DG and ABT-263, in that this treatment targets two independent weaknesses that are nearly 
ubiquitous among cancer cells: dependence on aerobic glycolysis and overexpression/dependence 
on an intracellular target. It has been shown that the anti-apoptotic subfamily of BCL-2 proteins 
are overexpressed in a large amount of leukemia subtypes [118, 130]. The combinatory therapy of 
2-DG and ABT-263 has already proven effective in vitro and in vivo in many tumor-based 
malignancies [131], and we have now shown in the present study that this combination of 
therapeutics could also serve as an effective treatment option in leukemias. Furthermore, it has 
been shown that altered ganglioside expression in cancers [50, 74, 76, 132], particularly 
upregulation of certain species such as GM3, is associated with a more aggressive and malignant 
phenotype in some cancers [50], such as melanoma [71, 133, 134]. This increased GM3 
expression has been shown to both increase resistance and negatively regulate apoptosis through 
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a Bcl-2-mediated mechanism [135]. Accordingly, inhibition of GCS in a drug-resistant cell line 
both reversed drug resistance and increase sensitivity to apoptosis through decreasing Bcl-2 
expression [136]. Given this association and the data presented in the current study, it would 
follow that treatment with the BCL2 proapoptotic family inhibitor ABT-263 may also function to 




Figure 10: Proposed mechanism of glycosphingolipid production via formation of substrates 
via glycolysis, the PPP and glycogenesis in highly glycolytic cells.  
Certain leukemia cells take up elevated levels of glucose, leading to increased flux through 
glycolysis and into the pentose phosphate pathway, glycogen synthesis, nucleotide biosynthesis 
and the TCA cycle. We hypothesize that increased flux into these pathways leads to the 
production of the rate-limiting substrates necessary for glycosphingolipid formation, namely, 









 The present work demonstrates a clear relationship between glycolytic metabolism and 
(glyco)sphingolipid biosynthesis in the context of elevated glucose availability. Future work 
would be based on strengthening this relationship and further characterizing its implication in 
cancer therapeutics. Data presented herein led us to formulate the hypothesis that increased 
glucose uptake results in elevated flux through glycolysis and the PPP, thereby forming the 
requisite substrates for GSL synthesis. Measurement of the metabolites implicated in GSL 
formation would be instrumental in supporting this hypothesis. The ensuing paragraphs will 
outline proposed experiments for detection of substrate uptake, metabolite detection and 
subsequent incorporation into GSLs. Unless otherwise indicated, “highly glycolytic cells” will be 
collectively used to indicate a general phenotype of increased glucose availability in both 
transformed and non-transformed cell types. 
 In addition to being a critical cellular antioxidant, NADPH plays a vital role as a 
reducing agent in many biosynthetic pathways. We proposed that NADPH produced by increased 
flux through the PPP in highly glycolytic cells aids in formation of GSLs, as it is used in both in 
fatty acid synthesis and in de novo ceramide synthesis. Simple measurement of NADPH could be 
performed using commercially available kits to observe the effect of glucose availability, as well 
as the effect of metabolic inhibitors used herein, such as 2-DG, 6-AN and PDMP/PPMP, on 
NADPH levels. If more detailed analysis of NADPH were required, a recently improved method 
for NADPH redox detection using deuterium for isotope labeling has been published [137]. This 
method utilizes 2H labeling and subsequent quantification via mass spectrometry or NMR, 
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allowing for distinction between NADH and NADPH production. Additionally, contribution of 
different subcellular locations to NADPH production can be determined using cellular 
fractionation techniques preceding quantification. This would be of importance in establishing 
whether putative increased NADPH in the ER, the site of de novo ceramide synthesis, plays a role 
in increased GSL formation. It is worth nothing that studies have suggested elevated glutamine 
metabolism may play as critical a role as the PPP in producing NADPH in neoplastic cells, thus it 
may be beneficial to look at players in this pathway as well using similar mechanisms [4].  
 UDP-Glucose and ceramide are utilized by glucosylceramide synthase to produce 
glucosylceramide. Data from animal models of DM1 have shown that UDP-glucose is elevated in 
response to increased glucose uptake [38, 39]. We hypothesized that increased glucose flux in 
highly glycolytic cells results in increased flux into glycogen synthesis, thereby increasing the 
formation of the requisite UDP-glucose. This phenomenon would be expected to occur more 
readily in neoplastic cells, which benefit from increased glycogen stores during times of stress or 
starvation [29, 30]. The enzyme responsible for UDP-glucose production is UDP-glucose 
pyrophosphorylase (or glucose-1-phosphate uridyltransferase) (UGP), which catalyzes the 
reversible synthesis of UDP-glucose from glucose-1-phosphate and UTP, releasing a 
pyrophosphate group. To determine the contribution of this pathway to GSL in highly glycolytic 
cells, expression and levels of UGP could be measured in both HG and leukemia cells to 
determine the effect of elevated glucose availability. I would also propose inhibition of UGP to 
emulate “normal” levels, both pharmacologically and genetically, to determine the effect on GSL 
levels. I suggest in both methods only partial reduction in UGP activity, seeing as UDP-glucose is 
necessary for a myriad of cellular functions and therefore its complete inhibition may produce 
exaggerated and off-target effects. Conversely, overexpression of the enzyme would further 
confirm (or deny) the contribution of UGP to GSL production. If our hypothesis were correct, 
inhibition of UGP would deplete GSL levels, while its overexpression would elevate them.   
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 Increased fatty acid synthesis to support the requisite increase in biomass demanded by the 
neoplastic cell has also been described as a component of deregulated cancer cell metabolism. 
Palmitoyl-CoA11 is utilized in the first step of de novo ceramide synthesis and is thus critical to 
sphingolipid metabolism and GSL formation. I propose using radiolabeled 13C-glucose to 
examine its incorporation into palmitate and subsequently into sphingolipids and GSLs. 
Following incubation with the radiolabeled substrate, quantification would be performed using 
mass spectrometry or NMR.  
 In addition to elucidating the role of individual metabolites in GSL formation, I also propose 
further confirmation of the role of individual pathways (i.e. glycolysis, the PPP, glycogen 
synthesis) in the production of GSLs in highly glycolytic cells. This would be performed through 
genetic inhibition and overexpression of the rate-limiting enzymes responsible for control of these 
pathways: hexokinase (glycolysis), glucose-6-phosphate dehydrogenase (PPP) and glycogen 
synthesis (glycogenesis). As previously discussed, I would suggest the use of partial knockdown 
via RNAi in order to elicit more physiologically-relevant effects and to avoid the off target effects 
of complete ablation of a metabolic pathway.  
 Some studies have suggested that the role of GCS inhibitors in sensitizing to cytotoxic and 
metabolic drugs is actually attributed to their action on p-glycoprotein, rather than GCS [98, 107]. 
As such, I would also suggest use of more “specific” GCS inhibitors (i.e. of the imino sugar 
subclass) to confirm the results attained herein and therein, so that future experiments can be 
properly compared and performed.  
 Furthermore, future work would further explore the hypothesis that sphingolipid metabolism 
can play a paradoxical role in drug resistance under certain conditions. Namely, evidence has 
suggested that GCS inhibitors PDMP and PPMP play a cytoprotective role in combination with 
daunorubicin when used at a sublethal doses [109], confirmed by preliminary data in our lab in 
                                                 
11 Palmitoyl-CoA: the CoA-charged version of palmitic acid, the first fatty acid produced by fatty acid 
synthesis and most common fatty acid in mammals 
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the present study. Namely, we would aim to determine if 1) data gathered in additional cancer cell 
models (i.e. adherent vs non-adherent, given the role of cell-surface GSLs in adhesion) would 
recapitulate the cytoprotective effect at sublethal doses previously published and herein, and 2) 
the same cytoprotective effect would occur in response to treatment with lethal doses (IC30) of 
PDMP/PPMP in combination with doxorubicin. If data suggest that sublethal doses are 
cytoprotective and lethal doses synergistic/additive/null effect, studies would proceed in the 
direction of investigating the molecular and metabolic basis underlying this effect. One 
hypothesis could incorporate the effect of GCS inhibition on drug efflux and the cytoprotective 
nature of p-glycoprotein. Briefly, it has been shown that p-glycoprotein is downregulated in 
response to GCS inhibition [96], and upregulated in response to GCS overexpression [95]. 
Intuitively, depletion of GlcCer, a p-gp substrate, via GCS inhibition would lead to compensatory 
upregulation of GCS to maintain GSL homeostasis. Given the suggested relationship between 
GCS and p-gp, this could consequently result in increased p-gp levels and subsequent drug efflux.  
 While cancer cell models are efficient for elucidation of biochemical pathways at the basic 
science level, they risk acquiring further mutations and differential phenotypes in addition to the 
original cancer. As such, further investigation of this phenomenon in a mouse model utilizing 
similar methods as described above (i.e. pharmacological and genetic inhibition of key metabolic 
enzymes, manipulation of glucose uptake in specific subsets of cells, etc.) would be critical in 
providing support for our hypothesis. Pulling from the in vitro studies, multiple facets of cancer 
cell metabolism and inhibition thereof will be addressed. This work would then move into 
analysis of patient-derived samples. Cancers should include hematological and solid tumor 
cancers of a variety of classes to observe if the phenotype is consistent across the board, in 
relation to the adherent nature of the cell. This is a critical consideration given the key role of 
GSLs in cell-cell adhesion, migration and metastasis. A panel of diverse neoplasms will allow 
comparison of our favorite metabolic pathways in the context of markedly different molecular 
aberrations. Such is the main argument for personalized medicine and clinical characterization of 
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the molecular and metabolic “traits” of cancer cells. I propose analyzing glucose uptake in the 
same manner as the present study, followed by measurement of pertinent sphingolipid and GSL 
species. Given that glutamine metabolism may also play a role in these cells, I would also suggest 
performing glutamine uptake assays, as well. The aforementioned rate-limiting enzymes should 
be analyzed for mRNA expression and protein levels via qPCR and western blot, respectively. 
Finally, synergism assays as described herein, i.e. PDMP/PPMP in combination with the 
respective cytotoxic drug, should be performed. All experiments should be compared to clinical 
scores: stage/score, aggressiveness, responsiveness to therapy, metastatic or non-malignant, etc. 
 Finally, we would like to more fully characterize the role of 2-DG and the glycolytic pathway 
in decreasing GSL levels, and if the decrease in GSL levels is a prerequisite for the synergistic 
effect observed in the combinatory treatment of 2-DG and 6-AN with ABT-263. In order to 
reconstitute GSL levels in the cell, we propose inhibiting GBA, the enzyme responsible for 
degradation of GlcCer, which would result in increased GlcCer and upstream GSLs.  
 As a parting note, the future method of lipid quantification is worth discussing in brief. 
HPLC-MS/MS is a very sensitive method for sphingolipid detection, given that in addition to 
quantitating overall lipid levels, it has the ability to also differentiate by fatty acid chain length. 
However, it can be extremely costly if outsourced, as is often the case. If a more cost-effective 
alternative were needed, it would be possible to measure the cause-effect relationship of 
inhibiting GSL production using flow cytometric analysis directed towards specific GSL 
molecules, such as GM1 or GD3 [138]. Furthermore, less sensitive methods such as TLC, used 
herein, are acceptable methods in combination with labeled substrates such as 13C-glucose. 
 
Caveats/Weaknesses 
The caveats of the present study are ones which should be addressed and accepted in all 
works which aim to target aberrant signaling and/or metabolic pathways as a means of treatment. 
Cancer cells are complex, multi-faceted, transformed versions of normal cells. No aberration 
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exists in and of itself, and rarely is any alteration in and of itself the sole reason for the 
transformation from normal to neoplastic. Signaling pathways are inherently interconnected and 
we must treat them as such; inhibition of one pathway will most likely result in eventual 
upregulation of another pathway; inhibition of one aspect of metabolism may result in increased 
reliance on another aspect of metabolism to support cancer growth. While glucose availability 
may impact GSL formation through the aforementioned pathways, the function of increased 
glucose uptake and utilization is by no means solely for production of GSLs, just as elevation of 
GSLs is most likely not the crippling Achilles heel of cancer. The goal of chemotherapeutics 
should be in simultaneously targeting multiple weaknesses of cancer cells in order to kill as many 
cells as possible in an attempt to avoid the inevitable resistance that will occur with single 
treatments.  
Furthermore, the present study discusses the use of metabolic inhibitors to target cells 
addicted to aerobic glycolysis. This approach will indiscriminately target all rapidly dividing 
cells, and thus be prone to the side effects of established chemotherapies. It has been suggested a 
“therapeutic window” exists for such treatments [51], although more work needs to be conducted 
to approve or disapprove this notion. It is possible that as nanotechnology advances, treatments 
may be targeted directly towards tumors using membrane-associated antigens, and thus would 
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FL5.12 HG   FL5.12 Hexokinase-I Glut-1  
G6PD    Glucose-6-phosphate dehydrogenase  
GlcCer    Glucosylceramide  
GBA    β-Glucocerebrosidase 
GCS    Glucosylceramide synthase 
GLUT1    Glucose transporter-1 
GSL    Glycosphingolipid 
HPLC-MS/MS  High performance liquid chromatography-mass spectrometry 
HK1    Hexokinase-I 
MDR    Multi-drug resistance 
MDR1    Multidrug resistance gene 
P-gp    P-glycoprotein 
PPP    Pentose phosphate pathway 
PDMP    1-phenyl-2-decanoylamino-3-morpholino-1-propanol 
PPMP    1-phenyl-2-palmitoylamino-3-N-morpholine-1-propanol  
S1P    Sphingosine-1-phosphate 
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